Table 3. The 3-year survival rates according to various clinical factors.
Factors | 3-y PFS (%) | 95% CI | P | 3-y OS (%) | 95% CI | P |
Gender | 0.117 | 0.118 | ||||
Male | 45.3 | 36.4–54.2 | 61.9 | 53.7–70.1 | . | |
Female | 77.8 | 68–87.6 | 88.1 | 80.2–96 | ||
Age | 0.011 | <0.001 | ||||
≤60 | 60 | 51.8–68.2 | 78.9 | 71.8–85.3 | ||
>60 | 21.8 | 8.4–35.2 | 21.8 | 8.4–35.2 | ||
ECOG performance status | 0.109 | 0.152 | ||||
0 | 60.4 | 48.5–72.3 | 76.7 | 66.8–86.6 | ||
1–2 | 52 | 43.6–60.4 | 63.9 | 55.7–72.1 | ||
B symptoms | 0.122 | 0.285 | ||||
Absent | 66.8 | 57.5–76.1 | 77.9 | 70.4–85.4 | ||
Present | 43 | 32.8–53.2 | 61.2 | 51.5–70.9 | ||
Serum LDH | 0.455 | 0.202 | ||||
Normal | 57.3 | 48.8–65.8 | 70.5 | 62.7–78.3 | ||
>normal | 44.7 | 29.6–59.8 | 68 | 58–78 | ||
LN involvement | 0.005 | 0.071 | ||||
Absent | 70.8 | 61.7–79.9 | 78.3 | 70.2–86.4 | ||
Present | 35.2 | 23.7–46.7 | 58.7 | 48.3–69.1 | ||
Ann Arbor stage | 0.042 | 0.304 | ||||
I | 68.3 | 58.6–78 | 76.2 | 67.4–85 | ||
II | 41.3 | 27.9–54.7 | 61.7 | 50.4–73 | ||
III–IV | 41.7 | 27.5–55.9 | 66.7 | 53.1–80.3 | ||
IPI | 0.067 | 0.053 | ||||
0–1 | 55.9 | 47.6–64.2 | 70.8 | 63.6–78 | ||
2–5 | 41.7 | 27.5–55.9 | 58.3 | 44.1–72.5 | ||
KPI | 0.064 | 0.251 | ||||
0 | 66 | 51.9–80.1 | 73.5 | 60–87 | ||
1 | 67.9 | 58.2–77.6 | 75.3 | 66.3–84.3 | ||
2 | 34.4 | 9.4–59.4 | 53.5 | 30.6–76.4 | ||
3–4 | 20.1 | 4.5–35.7 | 59.1 | 46.1–72.1 | ||
Lymphocytes | 0.286 | 0.217 | ||||
Normal | 49.3 | 40.8–57.8 | 62.5 | 54.4–70.6 | ||
<normal | 62.6 | 47–78.2 | 86.7 | 47.3–93.8 | ||
Monocytes | 0.432 | 0.861 | ||||
Normal | 51.6 | 41.5–61.7 | 69 | 60.1–77.9 | ||
>normal | 53.5 | 42.4–64.6 | 67.3 | 57.4–77.2 | ||
Serum IL-9 | <0.001 | 0.001 | ||||
≤3.49 | 68.7 | 59.4–78 | 86 | 80.6–91.4 | ||
>3.49 | 28.3 | 18.4–38.2 | 42.8 | 31.9–53.7 |
Abbreviations: PFS, progression-free survival; OS, overall survival; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; LN, local lymph node; IPI, international prognostic index; KPI, Korean prognostic index